Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 17,646

Document Document Title
WO/2013/092269A1
The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis,...  
WO/2013/088084A1
The invention relates to phytoecdysones for use in improving muscle quality in obese and/or sarcopenic mammals. More particularly, the invention relates to the obese mammals subjected to a low‑calorie diet. The phytoecdysones are advan...  
WO/2013/090205A2  
WO/2013/085016A1
General formula (I): The present invention pertains to: a pyridone derivate or a salt thereof represented by general formula (I); or a medicine containing the pyridone derivative or salt thereof as an active ingredient. [In the formula, ...  
WO/2013/082667A1
The invention provides a method for treating a condition in which growth hormone administration is beneficial, for treating osteoarthritis, for increasing chondrocyte, proteoglycan or collagen production or quality or repair or promoting...  
WO/2013/085017A1
General formula (I): The present invention pertains to: a pyridone derivate or a salt thereof represented by general formula (I); or a medicine containing the pyridone derivative or salt thereof as an active ingredient. [In the formula, ...  
WO/2013/085351A1
The present invention relates to a pharmaceutical composition comprising diaminodiphenylsulfone (dapsone, DDS) or the pharmaceutically acceptable salts thereof as active ingredients for preventing or treating diseases associated with mus...  
WO/2013/081094A1
The purpose of the present invention is to provide a compound that can act on mGluR5 selectively to inhibit the signaling of mGluR5. The present invention provides an imidazo[1,2-a]pyridine derivative typified by the compound shown below...  
WO/2013/079487A1
The present invention relates to an APJ receptor agonist or an apelinomimetic for the treatment or the prevention of a dysfunction associated with aging.  
WO/2013/081118A1
(Problem) To provide a novel compound having read-through activity, and a therapeutic agent for nonsense mutation diseases containing the compound. (Solution) A compound represented by the general formula (1), and a pharmaceutical compos...  
WO/2013/078261A1
The present invention provides methods for improving muscular function or treating a muscular disorder in an individual by administering to the individual a pharmacologically effective amount of a compound that inhibits microtubule-depen...  
WO/2013/074557A1
The present invention provides compositions and methods which involve specifically antagonizing GDFS and Activir) A. Sn certain embodftTtents, compositions are provided which comprise a GDF8-specifie binding protein and an Activin A-spec...  
WO/2013/074636A1
Agents, compositions, and medicaments that pertain to modulating the activity of muscle specific kinase receptor (MuSK) and methods and uses thereof to modulate MuSK activity are encompassed herein. Also encompassed are screening assays ...  
WO/2013/067591A1
The present disclosure relates generally to the field of pain management, including methods and formulations for the topical management of pain, such as localized pain. The present disclosure further teaches combination therapy to topica...  
WO/2013/067639A1
The present invention relates to uses and methods comprising one or more RANK/RANKL antagonists or of a pharmaceutical composition comprising one or more RANK/RANKL antagonists and a pharmaceutically acceptable carrier for treating neuro...  
WO/2013/064585A1
Compositions comprising mechanosensitive ion channel blockers, such as gadolinium, or N-cadherin antagonists or connexin 43 inhibitors enable musculoskeletal fibroproliferative disorders, such as Dupuytren's and other fibromatosis and li...  
WO/2013/063536A1
The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.  
WO/2013/057230A1
The present invention relates to whey protein micelles for use in the treatment and/or prevention of a condition linked to a reduced concentration of plasma amino acids in a patient. A further aspect of the invention is a meal replacemen...  
WO/2013/058194A1
Provided are a pharmaceutical product, a quasi-pharmaceutical product, a food, an animal food, and a material mixable thereto that have an excellent SRF signal activation effect and are highly safe. This SRF signal activating agent compr...  
WO/2013/059606A1
Disclosed are methods of treating a muscle disease and improving normal muscle function by administering a therapeutically effective amount of an isoprenoid antibiotic. Also disclosed are methods of upregulating hnRNP L and hnRNP L targe...  
WO/2013/057231A1
The present invention relates to a non-therapeutic use of whey protein micelles to enhance muscle protein synthesis in a subject. Further aspects of the invention are food compositions comprising whey protein micelles to be administered ...  
WO/2013/058229A1
Provided are a pharmaceutical product, a quasi-pharmaceutical product, a food, an animal food, and a material mixable thereto that are highly safe and have an excellent effect of, for example, increasing the amount of muscles. This agent...  
WO/2013/054866A8
The present invention provides an agent for preventing or treating HAM and containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as the active ingredient. The present invention also provides an agent for ameliorat...  
WO/2013/055385A3
The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enha...  
WO/2013/055385A2
The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enha...  
WO/2013/054866A1
The present invention provides an agent for preventing or treating HAM and containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as the active ingredient. The present invention also provides an agent for ameliorat...  
WO/2013/053795A1
The present invention generally relates to the field of medical nutrition. For example, the present invention provides a composition that can be used to treat, prevent and/or reverse muscle atrophy related to immobilization and its conse...  
WO/2013/055577A1
The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.  
WO/2013/045962A1
The invention refers to the use of compound of formula I or an N-oxide of the compound of formula I or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition for the prevention and/or t...  
WO/2013/049293A1
Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.  
WO/2013/045380A2
The present invention relates to mGluR5 positive allosteric modulators (PAM) and methods for identifying pharmaceutically acceptable compounds with high tolerability and safety, which method comprises the use of at least one non-competit...  
WO/2013/045885A1
The invention provides a method of treating mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) in a patient, comprising administering to the patient autologous erythrocytes that contain thymidine phosphorylase and are free of ...  
WO/2013/045380A3
The present invention relates to mGluR5 positive allosteric modulators (PAM) and methods for identifying pharmaceutically acceptable compounds with high tolerability and safety, which method comprises the use of at least one non-competit...  
WO/2013/049289A1
Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes, and for reducing weight gain. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.  
WO/2013/046335A1
[Problem] In a non-aqueous patch containing lidocaine, the adhesive force of the preparation tends to lower with an increase in the content of lidocaine. To release an effective amount of lidocaine from a patch to the skin, it is a commo...  
WO/2013/043580A2
The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide contain...  
WO/2013/043580A3
The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide contain...  
WO/2013/039197A1
An adenosine analog noraristeromycin (NAM) represented by this formula and having a selective inhibitory activity against IκB kinase α is used as: a therapeutic agent against recurring castration-resistant prostate cancer; a contracept...  
WO/2013/039244A1
Provided is an agent for stimulating skeletal muscle regeneration in muscle disease or myopathy. The agent for stimulating skeletal muscle regeneration contains chondroitinase as the active ingredient and accelerates regeneration of musc...  
WO/2013/038740A1
The present invention provides: a method for treating muscular atrophy; and a method and a means both for promoting muscle hypertrophy. Specifically, the present invention provides a method for screening for a substance or factor capable...  
WO/2013/040417A1
Amphiphilic cationic polymers comprising a biocompatible amphiphile linked to an organic cation are provided. The polymers complex with therapeutic agents and facilitate delivery of such therapeutic agents, particularly therapeutic nucle...  
WO/2013/035047A1
The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form(I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provid...  
WO/2013/035712A1
The purpose of the present invention is to provide a novel medicinal agent and a novel method both of which can be used for treating ALS (amyotrophic lateral sclerosis), preventing the progression of the phase of ALS, treating a symptom ...  
WO/2013/036875A1
The present invention relates to methods of producing chondrocytes, improving the phenotype of a chondrocyte population, promoting chondrogenesis, maintaining a cell population in a differentiated state or increasing the number of cells ...  
WO/2013/030569A2
The present invention discloses cell penetrating peptides and conjugates of a cell penetrating peptide and a cargo molecule.  
WO/2013/030569A3
The present invention discloses cell penetrating peptides (CPP or membrane translocating peptide) and their conjugates with cargo molecules. The peptides are useful as drug delivery systems, particularly as delivery vehicles for nucleoti...  
WO/2013/029431A1
Disclosed are tosylate salts of benzodiazepine derivatives, their polymorphic forms, preparation methods and uses thereof, in particular to a tosylate salt of 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1 ,4]benzodiazepine...  
WO/2013/031749A1
The present invention addresses the problem of providing a physical activity promoter that includes lactic acid bacteria from the human gut and/or a treated product of such lactic acid bacteria, or a food product composition for promotin...  
WO/2013/026099A1
The present disclosure provides proteins comprising antibody antigen binding domains that bind to Fn14 and uses thereof. The present disclosure also provides methods for treating wasting disorders, such as cachexia.  
WO/2013/024311A1
The invention refers to the use of an amidoxime derivative of formula (I) or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition for the prevention and/or treatment of muscle atrophy.  

Matches 251 - 300 out of 17,646